Evaluation of levamisole pharmacokinetics and milk excretion in dairy goats

LUPORI, J.; SALLOVITZ, J.; DOMINGUEZ, P.; FARIAS, C.; CADENAZZI, G; LANUSSE, C.; IMPERIALE, F.

Madison

Congreso; 27th Conference of the World Association for the Advancement of Veterinary Parasitology; 2019

World Association for the Advancement of Veterinary Parasitology

Introduction: Levamisole(LVM) is a nematodicidal compound available for veterinary medicaluse for over 50 years. Since the widespread development of drugresistance is a serious productive inconvenient, LVM is currentlyused extralabel as a therapeutic alternative in dairy sheep andgoats. Thus,  information on drug residual concentrationsin milk is needed to assure protect consumer`s safety. Thecurrent work aimed to evaluate the concentration profiles of LVMin plasma and its pattern of milk excretion in lactating dairygoats treated at different stages of lactation.Materialand Methods: Twelve(12) female Saanen dairy goats at early-mid stage of lactation (groupA) and at mid-late stage of lactation (group B) were orally treatedwith LVM (7.5 mg/kg) (Ripercol®, Zoetis). Blood and milksamples werecollected between 0 and 5 dayspost-treatment to characterize the plasma and milk dispositionkinetics. LVM concentrations in plasma and milk were determinedby HPLC with  UV detection.Results: LVMparent compound was detected in plasma and milk up to 8 h and 12h post-treatment, respectively. Plasma concentrations increasedprogressively to a maximum concentration (Cmax)of 0.89 ± 0.2 µg/ml at 0.27 h (group A) and 0.77 ± 0.3 µg/ml at0.2 h (group B). LVM milk residual concentrations were markedly lowerthanmeasuredin plasma.Conclusion:The pharmacokinetic results reported here confirm that LVM isexcreted by milk in lactating dairy goats. The residualconcentrations in milk (0.05 µg/ml) detected up to 12 h, should beconsidered before issuing any recommendation on the manufacturing ofmilk from dairy goats under antiparasitic treatment with LVM.